BACKGROUND: Transfusion-associated graft-versus-host disease (TA-GVHD) is a fatal complication of transfusion of blood products that usually affects immunocompromised patients. Articles reporting this condition in immunocompetent recipients are usually from countries that still have problems in irradiation of blood products. CASE REPORTS: This report presents fatal TA-GVHD in four immunocompetent patients referred from rural areas where blood irradiation is still not the routine procedure to our tertiary-care center between July 2004 and July 2005. A similar history and chronological order of events were observed: fresh whole-blood transfusion from relatives, fever, rash, liver dysfunction, diarrhea, and pancytopenia. Skin biopsies demonstrated Grade II to III GVHD involvement. Marrow biopsies showed hypoplasia. In two cases, HLA typing studies were performed. Donors were homozygous for a shared HLA haplotype in the patients. All cases were admitted to the intensive care unit within 3 weeks after transfusions with the diagnosis of sepsis, which rapidly progressed to septic shock and multiorgan failure. Another common observation was Candida albicans growth in blood cultures. Unfortunately, all died despite prompt and appropriate sepsis treatment, along with immunomodulatory therapy. CONCLUSION: TA-GVHD is probably more prevalent than reported in the literature. It must be considered in the differential diagnosis, if the patient with a recent transfusion history admits with fever, skin rash, abnormal liver function tests, and pancytopenia associated with hypoplastic marrow. In rural areas where gamma irradiation is not possible, the overall policy of transfusion (e.g., restriction of transfusion indications and alternative methods for pathogen inactivation) should be reassessed.
BACKGROUND: Transfusion-associated graft-versus-host disease (TA-GVHD) is a fatal complication of transfusion of blood products that usually affects immunocompromised patients. Articles reporting this condition in immunocompetent recipients are usually from countries that still have problems in irradiation of blood products. CASE REPORTS: This report presents fatal TA-GVHD in four immunocompetent patients referred from rural areas where blood irradiation is still not the routine procedure to our tertiary-care center between July 2004 and July 2005. A similar history and chronological order of events were observed: fresh whole-blood transfusion from relatives, fever, rash, liver dysfunction, diarrhea, and pancytopenia. Skin biopsies demonstrated Grade II to III GVHD involvement. Marrow biopsies showed hypoplasia. In two cases, HLA typing studies were performed. Donors were homozygous for a shared HLA haplotype in the patients. All cases were admitted to the intensive care unit within 3 weeks after transfusions with the diagnosis of sepsis, which rapidly progressed to septic shock and multiorgan failure. Another common observation was Candida albicans growth in blood cultures. Unfortunately, all died despite prompt and appropriate sepsis treatment, along with immunomodulatory therapy. CONCLUSION: TA-GVHD is probably more prevalent than reported in the literature. It must be considered in the differential diagnosis, if the patient with a recent transfusion history admits with fever, skin rash, abnormal liver function tests, and pancytopenia associated with hypoplastic marrow. In rural areas where gamma irradiation is not possible, the overall policy of transfusion (e.g., restriction of transfusion indications and alternative methods for pathogen inactivation) should be reassessed.
Authors: Karin Amrein; Ursula Posch; Cord Langner; Gregor Gorkiewicz; Christoph Högenauer Journal: Intensive Care Med Date: 2010-04-16 Impact factor: 17.440
Authors: John R Stehle; Michael J Blanks; Gregory Riedlinger; Jung W Kim-Shapiro; Anne M Sanders; Jonathan M Adams; Mark C Willingham; Zheng Cui Journal: BMC Cancer Date: 2009-09-15 Impact factor: 4.430
Authors: Judith Marsh; Gerard Socie; Andre Tichelli; Hubert Schrezenmeier; Britta Hochsmann; Antonio M Risitano; Monika Fuehrer; Albert N Bekassy; Elizabeth T Korthof; Anna Locasciulli; Per Ljungman; Andrea Bacigalupo; Bruce Camitta; Neal S Young; Jakob Passweg Journal: Br J Haematol Date: 2010-05-26 Impact factor: 6.998
Authors: Gavin M Bendle; Carsten Linnemann; Anna I Hooijkaas; Laura Bies; Moniek A de Witte; Annelies Jorritsma; Andrew D M Kaiser; Nadine Pouw; Reno Debets; Elisa Kieback; Wolfgang Uckert; Ji-Ying Song; John B A G Haanen; Ton N M Schumacher Journal: Nat Med Date: 2010-04-18 Impact factor: 53.440
Authors: Nicole D Zantek; Robert I Parker; Leo M van de Watering; Cassandra D Josephson; Scot T Bateman; Stacey L Valentine; Meghan Delaney Journal: Pediatr Crit Care Med Date: 2018-09 Impact factor: 3.624
Authors: Gerda C Leitner; Gerhard Hagn; Laura Niederstaetter; Andrea Bileck; Kerstin Plessl-Walder; Michaela Horvath; Vera Kolovratova; Andreas Tanzmann; Alexander Tolios; Werner Rabitsch; Philipp Wohlfarth; Christopher Gerner Journal: Biomolecules Date: 2022-09-07
Authors: Lucas Sacchini Del Lama; Evamberto Garcia de Góes; Paulo César Dias Petchevist; Edson Lara Moretto; José Carlos Borges; Dimas Tadeu Covas; Adelaide de Almeida Journal: PLoS One Date: 2013-06-07 Impact factor: 3.240